These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1466 related items for PubMed ID: 38507188

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Durability of Effectiveness Between Users of Once-Weekly Semaglutide and Dipeptidyl Peptidase 4 Inhibitors (DPP-4i) in US Adults with Type 2 Diabetes.
    Tan X, Liang Y, Gamble C, King A.
    Diabetes Ther; 2024 Feb; 15(2):427-445. PubMed ID: 38060149
    [Abstract] [Full Text] [Related]

  • 3. Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease.
    Tan X, Liang Y, Rajpura JR, Yedigarova L, Noone J, Xie L, Inzucchi S, de Havenon A.
    Cardiovasc Diabetol; 2023 Nov 20; 22(1):319. PubMed ID: 37985992
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. GLP-1RA vs DPP-4i Use and Rates of Hyperkalemia and RAS Blockade Discontinuation in Type 2 Diabetes.
    Huang T, Bosi A, Faucon AL, Grams ME, Sjölander A, Fu EL, Xu Y, Carrero JJ.
    JAMA Intern Med; 2024 Oct 01; 184(10):1195-1203. PubMed ID: 39133509
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Glucagon-like-peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes in diabetes in relation to achieved glycemic control. A Danish nationwide study.
    Zareini B, Sørensen KK, Pedersen-Bjergaard U, Loldrup Fosbøl E, Køber L, Torp-Pedersen C.
    J Diabetes; 2024 Jun 01; 16(6):e13560. PubMed ID: 38751369
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ.
    Diabetes Obes Metab; 2017 Apr 01; 19(4):524-536. PubMed ID: 27981757
    [Abstract] [Full Text] [Related]

  • 11. Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors for the treatment of diabetes mellitus in liver transplant recipients.
    Zheng K, Azhie A, You X, Naghibzadeh M, Tan E, Naimimohasses S, Sridhar VS, Gupta S, Chen S, Dash S, Tsien C, Selzner N, Lilly L, Jaeckel E, Woo M, Singh S, Cherney D, Bhat M.
    Diabetes Obes Metab; 2024 Oct 01; 26(10):4261-4272. PubMed ID: 39056216
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Pinelli NR, Hurren KM.
    Ann Pharmacother; 2011 Jul 01; 45(7-8):850-60. PubMed ID: 21730278
    [Abstract] [Full Text] [Related]

  • 14. Comorbidities and neighborhood factors associated with prescription of sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists among medically underserved populations.
    Ogunsanmi DO, Harrison AT, Pakker AR, Kovesdy CP, Bailey JE, Surbhi S.
    J Manag Care Spec Pharm; 2023 Jun 01; 29(6):699-711. PubMed ID: 37276038
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Glucagonlike peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors in ischemic strokes with diabetes 2.
    Hastrup S, Hedegaard JN, Andersen G, Rungby J, Johnsen SP.
    Eur J Neurol; 2024 Aug 01; 31(8):e16329. PubMed ID: 38715389
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 74.